{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:26:59Z","timestamp":1769041619496,"version":"3.49.0"},"reference-count":57,"publisher":"National Institute for Health and Care Research","issue":"3","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["11\/129\/261"],"award-info":[{"award-number":["11\/129\/261"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Most children with steroid-sensitive nephrotic syndrome have relapses that are triggered by upper respiratory tract infections. Four small trials, mostly in children already taking maintenance corticosteroid in countries of different upper respiratory tract infection epidemiology, showed that giving daily low-dose prednisone\/prednisolone for 5\u20137 days during an upper respiratory tract infection reduces the risk of relapse.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To determine if these findings were replicated in a large UK population of children with relapsing steroid-sensitive nephrotic syndrome on different background medication or none.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A randomised double-blind placebo-controlled trial, including a cost-effectiveness analysis.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n A total of 122 UK paediatric departments, of which 91 recruited patients.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n A total of 365 children with relapsing steroid-sensitive nephrotic syndrome (mean age 7.6\u2009\u00b1\u20093.5 years) were randomised (1\u2009:\u20091) according to a minimisation algorithm based on background treatment. Eighty children completed 12 months of follow-up without an upper respiratory tract infection. Thirty-two children were withdrawn from the trial (14 prior to an upper respiratory tract infection), leaving a modified intention-to-treat analysis population of 271 children (134 and 137 children in the prednisolone and placebo arms, respectively).<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n At the start of an upper respiratory tract infection, children received 6 days of prednisolone (15\u2009mg\/m2<\/jats:sup>) or an equivalent dose of placebo.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary outcome was the incidence of first upper respiratory tract infection-related relapse following any upper respiratory tract infection over 12 months. The secondary outcomes were the overall rate of relapse, changes in background treatment, cumulative dose of prednisolone, rates of serious adverse events, incidence of corticosteroid adverse effects, change in Achenbach Child Behaviour Checklist score and quality of life. Analysis was by intention-to-treat principle. The cost-effectiveness analysis used trial data and a decision-analytic model to estimate quality-adjusted life-years and costs at 1 year, which were then extrapolated over 16 years.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 384 upper respiratory tract infections and 82 upper respiratory tract infection-related relapses in the prednisolone arm, and 407 upper respiratory tract infections and 82 upper respiratory tract infection-related relapses in the placebo arm. The number of patients experiencing an upper respiratory tract infection-related relapse was 56 (42.7%) and 58 (44.3%) in the prednisolone and placebo arms, respectively (adjusted risk difference \u20130.024, 95% confidence interval \u20130.14 to 0.09; p<\/jats:italic>\u2009=\u20090.70). There was no evidence that the treatment effect differed when data were analysed according to background treatment. There were no significant differences in secondary outcomes between treatment arms. Giving daily prednisolone at the time of an upper respiratory tract infection was associated with increased quality-adjusted life-years (0.9427 vs. 0.9424) and decreased average costs (\u00a3252 vs. \u00a3254), when compared with standard care. The cost saving was driven by background therapy and hospitalisations after relapse. The finding was robust to sensitivity analysis.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n A larger number of children than expected did not have an upper respiratory tract infection and the sample size attrition rate was adjusted accordingly during the trial.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The clinical analysis indicated that giving 6 days of daily low-dose prednisolone at the time of an upper respiratory tract infection does not reduce the risk of relapse of steroid-sensitive nephrotic syndrome in UK children. However, there was an economic benefit from costs associated with background therapy and relapse, and the health-related quality-of-life impact of having a relapse.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Further work is needed to investigate the clinical and health economic impact of relapses, interethnic differences in treatment response, the effect of different corticosteroid regimens in treating relapses, and the pathogenesis of individual viral infections and their effect on steroid-sensitive nephrotic syndrome.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN10900733 and EudraCT 2012-003476-39.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 26, No. 3. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/wtfc5658","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T10:08:11Z","timestamp":1642759691000},"page":"1-94","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT"],"prefix":"10.3310","volume":"26","clinical-trial-number":[{"clinical-trial-number":"isrctn10900733","registry":"10.18810\/isrctn","type":"results"},{"clinical-trial-number":"2012-003476-39","registry":"10.18810\/euctr","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1642-1961","authenticated-orcid":true,"given":"Martin T","family":"Christian","sequence":"first","affiliation":[{"name":"Department of Paediatric Nephrology, Nottingham Children\u2019s Hospital, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-5446","authenticated-orcid":true,"given":"Nicholas JA","family":"Webb","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, University of Manchester, Academic Health Science Centre, Royal Manchester Children\u2019s Hospital, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-1431","authenticated-orcid":true,"given":"Rebecca L","family":"Woolley","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-7029","authenticated-orcid":true,"given":"Nafsika","family":"Afentou","sequence":"additional","affiliation":[{"name":"Health Economics Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7096-513X","authenticated-orcid":true,"given":"Samir","family":"Mehta","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1158","authenticated-orcid":true,"given":"Emma","family":"Frew","sequence":"additional","affiliation":[{"name":"Health Economics Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0669-3085","authenticated-orcid":true,"given":"Elizabeth A","family":"Brettell","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5366-233X","authenticated-orcid":true,"given":"Adam R","family":"Khan","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4737-2744","authenticated-orcid":true,"given":"David V","family":"Milford","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Birmingham Children\u2019s Hospital, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-941X","authenticated-orcid":true,"given":"Detlef","family":"Bockenhauer","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University College London, Department of Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-4518","authenticated-orcid":true,"given":"Moin A","family":"Saleem","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, University of Bristol, Department of Paediatric Nephrology, Bristol Royal Hospital for Children, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-5421","authenticated-orcid":true,"given":"Angela S","family":"Hall","sequence":"additional","affiliation":[{"name":"Leicester Children\u2019s Hospital, Leicester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-0246","authenticated-orcid":true,"given":"Ania","family":"Koziell","sequence":"additional","affiliation":[{"name":"Child Health Clinical Academic Group, King\u2019s College London, Department of Paediatric Nephrology, Evelina London Children\u2019s Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5904-1718","authenticated-orcid":true,"given":"Heather","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Royal Hospital for Sick Children, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-9940","authenticated-orcid":true,"given":"Shivaram","family":"Hegde","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, University Hospital of Wales, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric R","family":"Finlay","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Leeds Children\u2019s Hospital, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7426-0188","authenticated-orcid":true,"given":"Rodney D","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Southampton Children\u2019s Hospital, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-9286","authenticated-orcid":true,"given":"Caroline","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Alder Hey Children\u2019s Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5010-0398","authenticated-orcid":true,"given":"Karl","family":"McKeever","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Royal Hospital for Sick Children, Belfast, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-2813","authenticated-orcid":true,"given":"Wendy","family":"Cook","sequence":"additional","affiliation":[{"name":"Nephrotic Syndrome Trust (NeST), Taunton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-7541","authenticated-orcid":true,"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"key20220118110750152_ref1-bib1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1745-6215-15-147","article-title":"Short course daily prednisolone therapy during an upper respiratory tract infection in children with relapsing steroid-sensitive nephrotic syndrome (PREDNOS 2): protocol for a randomised controlled trial","volume":"15","author":"Webb","year":"2014","journal-title":"Trials"},{"key":"key20220118110750152_ref1-bib2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S0140-6736(85)91387-X","article-title":"Long-term outcome for children with minimal-change nephrotic syndrome","volume":"1","author":"Trompeter","year":"1985","journal-title":"Lancet"},{"key":"key20220118110750152_ref1-bib3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/s0140-6736(70)91093-7","article-title":"Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children","volume":"1","author":"Abramowicz","year":"1970","journal-title":"Lancet"},{"key":"key20220118110750152_ref1-bib4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001533.pub5","article-title":"Corticosteroid therapy for nephrotic syndrome in children (review)","volume":"3","author":"Hahn","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"key20220118110750152_ref1-bib5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1681\/ASN.2012070646","article-title":"Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome","volume":"24","author":"Teeninga","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"key20220118110750152_ref1-bib6","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.260","article-title":"A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment","volume":"87","author":"Yoshikawa","year":"2015","journal-title":"Kidney Int"},{"key":"key20220118110750152_ref1-bib7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/ki.2014.240","article-title":"Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome","volume":"87","author":"Sinha","year":"2015","journal-title":"Kidney Int"},{"key":"key20220118110750152_ref1-bib8","doi-asserted-by":"publisher","first-page":"l1800","DOI":"10.1136\/bmj.l1800","article-title":"Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation","volume":"365","author":"Webb","year":"2019","journal-title":"BMJ"},{"issue":"26","key":"key20220118110750152_ref1-bib9","doi-asserted-by":"publisher","DOI":"10.3310\/hta23260","article-title":"Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT","volume":"23","author":"Webb","year":"2019","journal-title":"Health Technol Assess"},{"key":"key20220118110750152_ref1-bib10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0022-3476(82)80692-6","article-title":"A report of the International Study of Kidney Disease in Children","volume":"101","author":"Early identification of frequent relapsers among children with minimal change nephrotic syndrome","year":"1982","journal-title":"J Pediatr"},{"key":"key20220118110750152_ref1-bib11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","article-title":"Idiopathic nephrotic syndrome in children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"key":"key20220118110750152_ref1-bib12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/archdischild-2015-309522","article-title":"Systematic review of the toxicity of short-course oral corticosteroids in children","volume":"101","author":"Aljebab","year":"2016","journal-title":"Arch Dis Child"},{"key":"key20220118110750152_ref1-bib13","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1136\/archdischild-2016-311535.57","article-title":"Long-course oral corticosteroid toxicity in children","volume":"101","author":"Aljebab","year":"2016","journal-title":"Arch Dis Child"},{"key":"key20220118110750152_ref1-bib14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1440-1754.2004.00285.x","article-title":"Clinical profile of children with nephrotic syndrome not on glucorticoid therapy, but presenting with infection","volume":"40","author":"Alwadhi","year":"2004","journal-title":"J Paediatr Child Health"},{"key":"key20220118110750152_ref1-bib15","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00467-009-1170-5","article-title":"Efficacy of zinc supplements in reducing relapses in steroid-sensitive nephrotic syndrome","volume":"24","author":"Arun","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0022-3476(86)80876-9","article-title":"Role of respiratory viruses in exacerbations of primary nephrotic syndrome","volume":"108","author":"MacDonald","year":"1986","journal-title":"J Pediatr"},{"key":"key20220118110750152_ref1-bib17","first-page":"337","article-title":"Infections in children with nephrotic syndrome","volume":"13","author":"Moorani","year":"2003","journal-title":"J Coll Physicians Surg Pak"},{"key":"key20220118110750152_ref1-bib18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000045684","article-title":"Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome","volume":"85","author":"Mattoo","year":"2000","journal-title":"Nephron"},{"key":"key20220118110750152_ref1-bib19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/adc.2007.116079","article-title":"Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial","volume":"93","author":"Abeyagunawardena","year":"2008","journal-title":"Arch Dis Child"},{"key":"key20220118110750152_ref1-bib20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2215\/CJN.01850310","article-title":"Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Gulati","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20220118110750152_ref1-bib21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s00467-003-1295-x","article-title":"The effects of corticosteroids on behavior in children with nephrotic syndrome","volume":"18","author":"Hall","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib22","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-017-3640-5","article-title":"Short courses of daily prednisolone during upper respiratory tract infections reduce relapse frequency in childhood nephrotic syndrome","volume":"32","author":"Abeyagunawardena","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib23","volume-title":"Sample Size Tables for Clinical Studies","author":"Machin","year":"2009","edition":"3rd"},{"key":"key20220118110750152_ref1-bib24","volume-title":"Manual for the Child Behavior Checklist and Revised Behavior Profile","author":"Achenbach","year":"1983"},{"key":"key20220118110750152_ref1-bib25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/11599120-000000000-00000","article-title":"Valuation of the Child Health Utility 9D Index","volume":"30","author":"Stevens","year":"2012","journal-title":"PharmacoEconomics"},{"key":"key20220118110750152_ref1-bib26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni","year":"2003","journal-title":"Ambul Pediatr"},{"key":"key20220118110750152_ref1-bib27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40273-017-0600-7","article-title":"Mapping the Paediatric Quality of Life Inventory (PedsQL\u2122) generic core scales onto the Child Health Utility Index \u2013 9 Dimension (CHU-9D) score for economic evaluation in children","volume":"36","author":"Lambe","year":"2018","journal-title":"PharmacoEconomics"},{"key":"key20220118110750152_ref1-bib28","volume-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","author":"Kidney Disease Improving Global Outcomes","year":"2012"},{"key":"key20220118110750152_ref1-bib29","unstructured":"Great Britain. Medicines for Human Use (Clinical Trials) Regulations 2004. London: The Stationery Office; 2004."},{"key":"key20220118110750152_ref1-bib30","unstructured":"Great Britain. Medicines for Human Use (Clinical Trials) Amendment Regulations 2006. London: The Stationery Office; 2006."},{"key":"key20220118110750152_ref1-bib31","volume-title":"Prednisolone 5mg Tablets","author":"Electronic medicines compendium","year":"2021"},{"key":"key20220118110750152_ref1-bib32","volume-title":"Immunisation Against Infectious Disease.","author":"Department of Health and Social Care","year":"1996"},{"key":"key20220118110750152_ref1-bib33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"key20220118110750152_ref1-bib34","unstructured":"Department of Health and Social Care (DHSC). Research Governance Framework for Health and Social Care. 2nd edn. 2005. London: DHSC; 2005."},{"key":"key20220118110750152_ref1-bib35","volume-title":"Risk-Adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products","author":"Medical Research Council, Department of Health and Social Care and Medicines and Healthcare products Regulatory Agency","year":"2011"},{"key":"key20220118110750152_ref1-bib36","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"key20220118110750152_ref1-bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2021.5189","article-title":"Evaluation of daily low-dose prednisolone during upper respiratory tract infection to prevent relapse in children with relapsing steroid-sensitive nephrotic syndrome: the PREDNOS randomized clinical trial","author":"Christian","year":"2021","journal-title":"JAMA Pediatr"},{"key":"key20220118110750152_ref1-bib38","doi-asserted-by":"crossref","unstructured":"Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data. Cham: Springer International; 2020. https:\/\/doi.org\/10.1007\/978-3-030-47622-9","DOI":"10.1007\/978-3-030-47622-9"},{"key":"key20220118110750152_ref1-bib39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An introduction to Markov modelling for economic evaluation","volume":"13","author":"Briggs","year":"1998","journal-title":"PharmacoEconomics"},{"key":"key20220118110750152_ref1-bib40","volume-title":"Avoidable Mortality in the UK: 2019","author":"Office for National Statistics","year":"2021"},{"key":"key20220118110750152_ref1-bib41","volume-title":"Unit Costs of Health and Social Care 2019","author":"Curtis","year":"2019"},{"key":"key20220118110750152_ref1-bib42","volume-title":"NHS National Schedule of Reference Costs 2018\/19","author":"NHS"},{"key":"key20220118110750152_ref1-bib43","volume-title":"BNF for Children (Online)","author":"Paediatric Formulary Committee","year":"2020"},{"key":"key20220118110750152_ref1-bib44","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013."},{"key":"key20220118110750152_ref1-bib45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11136-012-0119-5","article-title":"Measuring preference-based quality of life in children aged 6\u20137 years: a comparison of the performance of the CHU-9D and EQ-5D-Y \u2013 the WAVES pilot study","volume":"22","author":"Canaway","year":"2013","journal-title":"Qual Life Res"},{"key":"key20220118110750152_ref1-bib46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jval.2012.07.011","article-title":"Measuring and valuing health benefits for economic evaluation in adolescence: an assessment of the practicality and validity of the child health utility 9D in the Australian adolescent population","volume":"15","author":"Stevens","year":"2012","journal-title":"Value Health"},{"key":"key20220118110750152_ref1-bib47","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s004670100021","article-title":"Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK","volume":"16","author":"McKinney","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib48","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1164\/ajrccm\/152.4_pt_2.s4","article-title":"The clinical impact of human respiratory virus infections","volume":"152","author":"Denny","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"key20220118110750152_ref1-bib49","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0022-3476(83)80582-4","article-title":"Risk of relapse in steroid-sensitive nephrotic syndrome: effect of stage of post-prednisone adrenocortical suppression","volume":"103","author":"Leisti","year":"1983","journal-title":"J Pediatr"},{"key":"key20220118110750152_ref1-bib50","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00467-018-4071-7","article-title":"Efficacy of low-dose daily versus alternate-day prednisolone in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial","volume":"34","author":"Yadav","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib51","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00467-011-1961-3","article-title":"Weight or body surface area dosing of steroids in nephrotic syndrome: is there an outcome difference?","volume":"26","author":"Saadeh","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib52","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1093\/ndt\/gfq097","article-title":"Behavioural abnormalities in children with nephrotic syndrome","volume":"25","author":"Mishra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"key20220118110750152_ref1-bib53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1191\/0962280202sm304ra","article-title":"Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods","volume":"11","author":"O\u2019Brien","year":"2002","journal-title":"Stat Methods Med Res"},{"key":"key20220118110750152_ref1-bib54","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.13371019","article-title":"Response to first course of intensified immunosuppression in genetically stratified steroid resistant nephrotic syndrome","volume":"15","author":"Mason","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20220118110750152_ref1-bib55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00467-016-3458-6","article-title":"Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children","volume":"32","author":"Raja","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib56","first-page":"1647","article-title":"Lower prednisolone dosing for nephrotic syndrome relapse: a prospective, randomised study","volume":"32","author":"Borovitz","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"key20220118110750152_ref1-bib57","first-page":"1980","article-title":"Low versus conventional dose prednisolone for nephrotic syndrome relapses: randomised-controlled, non-inferiority trial","volume":"34","author":"Sheikh","year":"2019","journal-title":"Pediatr Nephrol"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/WTFC5658\/WTFC5658.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:39:15Z","timestamp":1692113955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/WTFC5658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["10.3310\/WTFC5658"],"URL":"https:\/\/doi.org\/10.3310\/wtfc5658","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"10-2012","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"1-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"6-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}